Finland· FI-REL-REL64192
Zepzelca
A lurbinectedin product containing lurbinectedin, registered in Finland by Pharma Mar S.A.. The same ATC class is registered in 8 of our 19 countries.
Checked against Fimea (Finland) on
Informational only — not a medical device.
Where it is registered
Lurbinectedin is registered in 8 of 19 countries.
Countries holding a registration under ATC L01XX69 (lurbinectedin), each read from that country’s own register.
- This record: Finland, from Fimea (Finland)
- 6 of them publish a price we can compare per daily dose
Lurbinectedin · ATC L01XX69
8 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Finlandprice
- Netherlands
- Polandprice
- Switzerlandprice
- United Statesprice
The record
At a glance
Fimea (Finland)- Active substance
- Lurbinectedin
- Manufacturer
- Pharma Mar S.A.
- Country
- Finland (FI)
- ATC code
- L01XX69
- ATC class
- Lurbinectedin
- Reimbursed
- Not published by this register
- Source register
- Fimea (Finland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
203 interactions on record for lurbinectedin.
Graded by severity as the source publishes them — 60 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Lurbinectedin · interactions on record
203 records
- 60 severe
- 142 moderate
- 1 minor
Most severe, free to view
- AprepitantA04AD12severe
- DexamethasoneH02AB02severe
- KetoconazoleH02CA03severe
- ChloramphenicolJ01BA01severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Lurbinectedin in 9 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumZepzelca 4 mgPharma Mar
- CzechiaZEPZELCAPharma Mar, S.A., Madrid
- SpainZEPZELCA 4 MG POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSIONPharma Mar S.A.
- PolandZepzelcaPharma Mar, S.A.
- SwedenZepzelca 4 mg Pulver till koncentrat till infusionsvätska, lösningPharma Mar SA
- NetherlandsZEPZELCA 2 mg poeder voor concentraat voor oplossing voor infusiePharma Mar S.A.
- United StatesZEPZELCAJazz Pharmaceuticals, Inc.
- CanadaZEPZELCAJAZZ PHARMACEUTICALS IRELAND LIMITED
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Zepzelca
- Liechtenstein · Zepzelca
- Norway · Zepzelca
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b45d3bb8-2750-4dd5-9937-1f847207ed1d GET /v1/drugs/b45d3bb8-2750-4dd5-9937-1f847207ed1d?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"ddd": null,
"form": "kuiva-aine välikonsentraatiksi infuusionestettä varten, liuos",
"route": "Laskimoon",
"ddd_unit": null,
"strength": "4 mg",
"atc_label": "lurbinektediini",
"ma_number": null,
"auth_status": "Myyntilupa myönnetty",
"eu_ma_number": "EU/1/26/2032/002",
"fimea_rel_id": "REL64192",
"authorised_at": "2026-05-29"
}See everything about lurbinectedin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.